您当前的位置:
Olmesartan medoxomil (Synonyms: 奥美沙坦酯; CS 866)
目录号: PC15672 纯度: ≥98%
CAS No. :144689-63-4
商品编号 规格 价格 会员价 是否有货 数量
PC15672-25mg 25mg ¥637.00 请登录
PC15672-50mg 50mg ¥891.00 请登录
PC15672-100mg 100mg ¥1528.00 请登录
PC15672-200mg 200mg ¥2293.00 请登录
PC15672-10mM (in 1mL DMSO) 10mM (in 1mL DMSO) ¥637.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Olmesartan medoxomil
中文别名
奥美沙坦酯;2,3-二羟基-2-丁烯基-4-(1-羟基-1-甲基乙基)-2-丙基-1-[4-(2-1H-四唑-5-苯基)苄基]咪唑-5-羧酸酯环-2,3-碳酸酯;奥美沙坦;奥美沙坦(酯);奥美沙坦酯 EP标准品;奥美沙坦酯 USP标准品;奥美沙坦酯标准品;奥美沙坦酯标准品(JP);奥美沙坦酯片;奥美沙坦酯系统适用性 EP标准品;野生地榆提取物;奥美沙坦中间体
英文名称
Olmesartan medoxomil
英文别名
olmesartan medoxomil;olmetec;cs-866;MEDOXOMIL;1H-IMIDAZOLE-5-CARBOXYLIC ACID, 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-, (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER;4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER;2-Butyl-4-(1-hydroxy-1-methylethyl)-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;Olmesartan;Olmesartan Medoximil;(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl.5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2\'-(1H-tetrazol-5-yl)-[1,1\'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate;CS 866;OMST;4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;Benicar;Olmesartan (medoxomil);6M97XTV3HD;C29H30N6O6;(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate;1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester;1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-
Cas No.
144689-63-4
分子式
C29H30N6O6
分子量
558.59
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC50 of 66.2 μM.

性状

Solid

IC50 & Target[1][2]

IC50: 66.2 μM (angiotensin II receptor)

体外研究(In Vitro)

Inhibition of Arachidonic acid (AA) metabolism by angiotensin II receptor blockers (ARBs) is detected in a concentration-dependent manner with IC50 of Olmesartan (66.2 μM). Olmesartan medoxomil (OLM) is a potent and selective angiotensin AT1 receptor blocker.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

The efficacy of Olmesartan (20 mg/kg) studied in db/db diabetic mice for a period of 12 weeks starting from week 10 to 12 of age. The db/db mice have 11.7 fold increased albuminuria in comparison to control mice at week 22 to 24 of age. Twelve weeks Olmesartan administration significantly reduces albuminuria in db/db mice by 77% as compared with placebo treated db/db mice. The albumin/creatinine ratio (ACR) is increased in db/db mice in comparison to control mice by 7.1 fold and Olmesartan treatment significantly decreases ACR by 59% in db/db mice.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
溶解度数据
体外研究: 

DMSO : 50 mg/mL (89.51 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7902 mL 8.9511 mL 17.9022 mL
5 mM 0.3580 mL 1.7902 mL 3.5804 mL
10 mM 0.1790 mL 0.8951 mL 1.7902 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2.08 mg/mL (3.72 mM); Clear solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (3.72 mM) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.72 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.72 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.72 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.72 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2